MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

United Therapeutics Corp

Suletud

SektorTervishoid

306.29 -0.5

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

301.3

Max

311.13

Põhinäitajad

By Trading Economics

Sissetulek

-7.8M

301M

Müük

-13M

736M

P/E

Sektori keskmine

12.506

63.778

Aktsiakasum

6.19

Kasumimarginaal

40.943

Töötajad

1,305

EBITDA

6.3M

424M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+25.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-2.7B

14B

Eelmine avamishind

306.79

Eelmine sulgemishind

306.29

Uudiste sentiment

By Acuity

50%

50%

173 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

United Therapeutics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. okt 2024, 15:14 UTC

Suurimad hinnamuutused turgudel

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28. jaan 2025, 10:30 UTC

Peamised uudised

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Võrdlus sarnastega

Hinnamuutus

United Therapeutics Corp Prognoos

Hinnasiht

By TipRanks

25.34% tõus

12 kuu keskmine prognoos

Keskmine 384.64 USD  25.34%

Kõrge 460 USD

Madal 293 USD

Põhineb 12 Wall Streeti analüütiku instrumendi United Therapeutics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

8

Osta

3

Hoia

1

Müü

Tehniline skoor

By Trading Central

298.6 / 307.64Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

173 / 386 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.